Physician profile
Jaclyn Birn
NPI 1205353919
$749.78
in general payments reported to CMS, 2019-2025
16 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $258 · 2024: $263 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $147.28 | 2023 | Optimizer |
| Corium, LLC | $95.94 | 2024 | Azstarys |
| Abbvie INC. | $80.09 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.86 | 2024-2025 | Caplyta |
| Indivior INC. | $53.11 | 2024-2025 | Sublocade |
| Alkermes, INC. | $47.77 | 2025 | Aristada, Vivitrol, Lybalvi |
| Pfizer INC. | $32.96 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $30.01 | 2025 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $29.68 | 2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $29.10 | 2024 | Rexulti |
| Alnylam Pharmaceuticals INC. | $26.78 | 2023 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $24.04 | 2023 | |
| Supernus Pharmaceuticals, INC. | $23.99 | 2025 | Qelbree |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.91 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $13.82 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $13.44 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclyn Birn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.